cabergoline / Generic mfg. - LARVOL DELTA

Carbergoline for Antipsychotic Induced Hyperprolactinemia. (clinicaltrials.gov) - P4 | N=146 | Not yet recruiting | Sponsor: Zealand University Hospital

Head-to-Head • New P4 trial • CNS Disorders

Radiotherapy regimens and concurrent Cabergoline use for non-functioning pituitary neuroendocrine tumors: a large, single-center cohort. (PubMed, Endocrine) - No abstract available

Journal • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Solid Tumor

Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic. (PubMed, J Psychiatr Res) - "Male sex and higher cabergoline doses were associated with ICD development in the overall population but not in the subgrop of patients that had a documented screening. Other suspected risk factors, including psychiatric comorbidity and testosterone therapy, were not associated with development of ICD-adding nuance to prior findings. Screening was infrequent and disproportionately associated with ICD detection, suggesting underdiagnosis due to lack of proactive assessment. These results highlight the need for universal, standardized ICD screening in prolactinoma patients prior to and during cabergoline treatment."

Journal • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • Psychiatry

Dopamine Agonist Therapy Induced Fatal Pneumocephalus in Giant Prolactinoma. (PubMed, JCEM Case Rep) - "Dopamine agonist (DA) cabergoline (0.25 mg twice weekly) was initiated, and serum prolactin levels reached 3941 ng/mL (SI: 171.3 nmol/L) after 2 doses...Our case and review of 7 published cases of DA-induced pneumocephalus highlights male predominance, median tumor size of 5.5 cm (range, 4-9.5 cm), and onset within 1 to 12 weeks of initiation of DA therapy. Hence, for giant prolactinomas after DA initiation, it is essential to recognize the symptom complex associated with this rare life-threatening complication, pneumocephalus, and offer emergency surgical intervention."

Journal • Endocrine Disorders • Oncology • Pain • PRL

Psychosis after lactation inhibition with cabergoline (PubMed, Ugeskr Laeger) - "She was admitted with moderate depression following a suicide attempt, and started on cabergoline and sertraline, with initial improvement of the depressive symptoms. Symptoms rapidly improved with antipsychotics and ECT. Due to the long half-life of cabergoline, this case potentially highlights a rare but serious adverse effect of cabergoline."

Journal • CNS Disorders • Depression • Postpartum Depression • Psychiatry

Cabergoline for the Treatment of Chronic Pain Due to Endometriosis (clinicaltrials.gov) - P2 | N=129 | Completed | Sponsor: Boston Children's Hospital | Trial completion date: Jun 2026 ➔ Jan 2026 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Endometriosis • Gynecology • Pain • Women's Health

The Differences Between Dopamine Agonist-Resistant and -Non-Resistant Prolactinomas: Are There Any Predictors of a Good Response? (PubMed, Biomedicines) - "On the other hand, early radiological tumor shrinkage may predict favorable treatment outcomes. However, new markers of DA resistance, particularly molecular ones, should be identified."

Journal • Oncology • PRL

Surgical Outcomes in Knosp grade 3 or 4 macroprolactinomas: What role does debulking surgery play? (PubMed, World Neurosurg) - "Surgery was effective at addressing visual compromise in cavernous sinus invasive prolactinomas but had a limited effect on prolactin control and the ability to reduce dopamine agonist use."

Journal • Oncology

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off-target activity. (PubMed, Br J Pharmacol) - "Matsupexole is a promising future, potentially best-in-class dopamine receptor agonist for treating PD."

Journal • Preclinical • Cardiovascular • CNS Disorders • Heart Failure • Movement Disorders • Parkinson's Disease • Sleep Disorder

A sexually dimorphic neuronal cluster in the mouse medial amygdala responds to male sexual status. (PubMed, Proc Natl Acad Sci U S A) - "However, treatment with cabergoline, a potent inhibitor of prolactin secretion, did not prevent DIMPLE labeling in females or in postmating males. Given the established role of the MeApd in social and reproductive behaviors, we hypothesize that DIMPLE may support neural mechanisms underlying female-typical behavior and potentially contribute to postmating behavioral shifts in males."

Journal • Preclinical • FOS

Widespread invasion of a giant prolactinoma via valveless venous channels: illustrative case. (PubMed, J Neurosurg Case Lessons) - "To the authors' knowledge, this is the first documented case illustrating extensive venous-mediated spread of a pituitary adenoma through valveless venous networks involving the CS, orbital, and clival regions, and it provides a plausible mechanism for the enhanced invasive nature of prolactin-secreting tumors. This case underscores the need for thorough imaging and endocrine evaluation before considering the surgical management of suspected invasive pituitary lesions. https://thejns.org/doi/10.3171/CASE25891."

Journal • Hematological Disorders • Oncology • Ophthalmology • Pituitary Gland Carcinoma

Fertility and pregnancy in patients with prolactinoma. (PubMed, Best Pract Res Clin Endocrinol Metab) - "Treatment with dopamine agonists, primarily cabergoline, can achieve normoprolactinemia and restoration of the gonadal axis within 6-12 months in most patients...If the gonadal axis does not recover and fertility is desired, clomiphene citrate and other assisted reproductive techniques may be utilized...Breastfeeding is typically uneventful. This review addresses the principal mechanisms of infertility in hyperprolactinemia, in both women and men, as well as treatment approaches to achieving conception and recommendations for follow-up before, during, and after delivery."

Journal • Review • Infertility • Oncology • Pituitary Gland Carcinoma • Sexual Disorders

Endoscopic surgery for noninvasive prolactinomas: A large multicenter, single-arm, retrospective study (PRLomaSaR). (PubMed, Endocrine) - No abstract available

Journal • Retrospective data

Parkinson's Disease & Cardiovascular Disease: A Narrative Review. (PubMed, Trends Cardiovasc Med) - "Dopamine agonists pergolide and cabergoline are associated with valve regurgitation, but this seems to be drug-related rather than caused by PD. Our review consolidates existing research to highlight the importance of recognizing cardiovascular manifestations in PD, which may present before motor symptoms. This has important implications for earlier diagnosis, better screening, and more effective management of PD."

Journal • Review • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Hypertension • Hypotension • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial. (PubMed, Obstet Gynecol) - P2 | "Cabergoline is an effective and well-tolerated medication to prevent breast symptoms after early second-trimester abortion or pregnancy loss."

Clinical • Journal • Pain

Sex- and Age-Specific Metabolic Outcomes of Prolactin Normalisation in Hyperprolactinaemia. (PubMed, Clin Endocrinol (Oxf)) - "PRL normalisation with cabergoline was associated with modest improvements in conventional lipid fractions and a more consistent reduction in the TyG index, suggesting a preferential impact on insulin-resistance-related pathways. The absence of independent effects of sex, age, PRL dynamics, or cabergoline exposure on lipid changes underscores the need for cautious interpretation of statistically significant but small absolute shifts."

Journal • Endocrine Disorders • PRL

Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas. (PubMed, Endocr Oncol) - "This case, along with previous data showing GH and structural responses to cabergoline in individuals with acromegaly and hyperprolactinaemia, argue for a role for cabergoline monotherapy in the treatment armamentarium of GH and PRL-PAs, noting that some tumours may exhibit a significant treatment response as observed here. GH and PRL-PA is a typically aggressive form of pituitary adenoma.Cabergoline monotherapy can be an effective treatment option for select case of GH and PRL-PA, resulting in both biochemical and structural responses.Some GH and PRL-PAs may exhibit a 'hyper-response' to cabergoline with rapid, profound hormone reduction and/or tumour shrinkage."

Journal • Monotherapy • Acromegaly • Endocrine Disorders • Neuroendocrine Tumor • Oncology • Ophthalmology • Pituitary Gland Carcinoma • Solid Tumor

Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes. (PubMed, Pituitary) - "Duration and cumulative dose of presurgical CAB use do not correlate with quantitative measures of tumor fibrosis and do not reliably predict the degree of fibrosis at surgery or the likelihood of surgical remission."

Journal • Retrospective data • Fibrosis • Immunology • Oncology

Histological Evidence of familial GH-PitNET Associated with Germline MAX Mutation. (PubMed, Eur J Endocrinol) - "Despite multimodal therapy (lanreotide, cabergoline, two debulking surgeries), disease control was achieved only after pasireotide and adjuvant proton therapy. The same variant was found in her father, who had a smaller intrasellar macroadenoma causing acromegaly. This familial observation provides the functional evidence that MAX is a driver in GH-PitNET and a candidate gene for PitNET predisposition."

Journal • Acromegaly • Endocrine Disorders • Neuroendocrine Tumor • Oncology • Solid Tumor • MAX

A PRELIMINARY REPORT ON ACCESSIBILITY, AFFORDABILITY, AND AVAILABILITY OF MEDICINES FOR PARKINSON (ADPD 2026) - "The most available medicines were for autonomic symptoms such as omeprazole (98.28%), sildenafil (89.7%), bisacodyl (84.5%), tadalafil (60.3%), and for psychiatric symptoms such as haloperidol (50%) and fluoxetine (48.3%). Among dopaminergic medicines, carbidopa/levodopa was always available in 19% of pharmacies, dopamine agonists in 13.8% (bromocriptine), 6.9% (cabergoline), and 1.7% (ropinirole), and monoamine oxidase B inhibitors in 1.72%...Affordable medicines were those always available in the reference public hospital pharmacy, such as the antipsychotics haloperidol and risperidone, the anticholinergic trihexyphenidyl, and the antidepressant fluoxetine... Similar to other low-income countries, there is poor access to PD medicines in Malawi`s pharmacies due to regulatory, supply chain, and financial barriers."

CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Study of Clinical Profile and Early Response to Dopamine Agonist Therapy in Patients of Hyperprolactinemia: Experience at a Tertiary Care Centre of Nepal. (PubMed, Indian J Endocrinol Metab) - "A tumour volume reduction of ≥50% was found in 72.7% (8/11) macroadenomas as compared to 50% (7/14) microadenomas in our study. Cabergoline was highly efficacious for treatment of both tumoural and non-tumoural hyperprolactinemia with significant early clinical, biochemical, and radiological response to treatment."

Journal • Oncology

Update and practical recommendations for the use of medical treatment of Cushing´s syndrome. (PubMed, Endocr Rev) - "Currently available medical treatments include adrenal steroidogenesis inhibitors that block cortisol secretion (ketoconazole, levoketoconazole, metyrapone, osilodrostat, mitotane, and etomidate), drugs that modulate pituitary ACTH secretion (pasireotide and cabergoline), and drugs that block peripheral glucocorticoid receptors (mifepristone). In this review, we summarize the main indications for medical treatment in CS, the mechanism of drug action, efficacy, recommended doses, and safety of the currently available drugs, as well as potential future treatments. We also discuss titration and block-and-replace approaches for control of hypercortisolism and provide recommendations for the use and monitoring of medical treatment in CS, including patients with endogenous hypercortisolism in special situations such as pregnancy, cyclic CS and mild autonomous cortisol secretion."

Journal • Cushing’s Disease • Endocrine Disorders

Hyperprolactinemia and migraine-like headache: A case report and literature review (EHF-EHC 2025) - "She was treated with bromocriptine for three months, achieving complete headache resolution...Repeat MRI showed a pituitary microadenoma, and cabergoline was reinitiated, with significant headache improvement...Eletriptan was prescribed for acute attacks... This case supports the role of PRL in migraine-like headaches via neuromodulatory effects, independent of tumor mass. PRL receptors in trigeminal pathways suggest a sensitization mechanism. Dopamine agonists may relieve symptoms, even without tumor shrinkage, indicating a hormonal component."

Case report • Clinical • Review • CNS Disorders • Endocrine Disorders • Gynecology • Migraine • Pain

EXPRESS: SGLT2 inhibitor therapy in diabetic cats: first clinical experiences with non-ideal candidates. (PubMed, J Feline Med Surg) - "In addition, it reports on the concurrent use of other treatments, including cabergoline and insulin...Furthermore, the availability of ketone concentrations in both urine and/or blood provided valuable insight into the metabolic changes associated with this new treatment. The role of ketone monitoring in predicting treatment response and identifying potential adverse effects represents another important area for future research."

Journal • Diabetes • Metabolic Disorders • Nephrology • Renal Disease

Giant Prolactinoma: Challenges in Management. (PubMed, AACE Endocrinol Diabetes) - "First-line medical management includes dopamine agonists such as cabergoline and bromocriptine. The dilemma between medical management and surgical management occurs during initial presentation of giant prolactinoma with VF defect. Our case report highlights the challenges and complications encountered in the treatment of a patient with giant prolactinoma."

Journal • Endocrine Disorders • Hematological Disorders • Nephrology • Oncology • Pain • Pituitary Gland Carcinoma • Renal Disease • PRL